BI 44370 TA tablet
Sponsors
Boehringer Ingelheim
Conditions
HealthyMigraine Disorders
Phase 1
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
CompletedNCT00743015
Start: 2008-09-30Updated: 2013-11-01
Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers
CompletedNCT02215018
Start: 2007-04-30Updated: 2014-08-13